We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Diagnostic for C. difficile Eliminates Extraction Step

By LabMedica International staff writers
Posted on 19 May 2011
A new Clostridium difficile diagnostic test enables processing of up to 94 patient specimens in about an hour.

The Simplexa C. More...
difficile universal direct test is performed on liquid or unformed human stool samples, and detects toxin-producing strains of C. difficile, including NAP1/B1/027. The new CE marked in vitro diagnostic (IVD) test enables fast, high volume lab testing, eliminating the traditional extraction step.

The C. difficile diagnostic is the first test from the Focus Diagnostics (Cypress CA, USA) Simplexa product line for the hospital-acquired infection (HAI) market. It was unveiled by Focus together with the CE marked Simplexa Epstein Barr (EBV) and BK Virus tests during the European Congress of Clinical Microbiology and Infectious Disease (ECCMID) Tradeshow, which took place May 7-10, 2011, in Milan (Italy). The three Simplexa tests are CE marked and available in Europe.

Simplexa tests are run on the 3M Integrated Cycler and employ real-time polymerase chain reaction (RT-PCR) to detect viruses, bacteria, and other agents qualitatively and quantitatively.

C. difficile infection (CDI) is a bacterial infection that generally affects patients over 65 in age, on prolonged use of broad-spectrum antibiotics, and those who have recently undergone gastrointestinal surgery or are immunocompromised. In major European Union (EU) countries, such as Belgium, Denmark, France, Germany, Italy, Netherlands, Spain and the United Kingdom, CDI is estimated to be responsible for 1.1 in 1,000 hospital admissions and is expected to double over the next four decades.

"Clostridium difficile is a common cause of antibiotic-associated diarrhea and an extremely important and serious hospital-acquired infection," said Jay M. Lieberman, MD, medical director for Quest Diagnostics (Madison, NJ, USA) and Focus Diagnostics. "C. difficile infections (CDI) range in severity from mild diarrhea to life-threatening pseudomembranous colitis, and result in significant suffering and deaths. Timely diagnosis is essential for clinicians when treating patients presenting with possible C. difficile disease." Focus Diagnostics is a wholly owned subsidiary of Quest Diagnostics.

Related Links:
Focus Diagnostics
Quest Diagnostics


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.